Bill & Melinda Gates Foundation

Leinco Technologies develops and supplies high-purity monoclonal antibodies, recombinant proteins, and related reagents for diagnostics, biopharmaceutical research, and flow cytometry. The company focuses on monoclonal antibody development, in vitro production of antibodies and proteins, antibody conjugations, and associated services, including cell banking, optimization, and adaptation, to support early discovery programs and the development of protein therapeutics.

ReciBioPharm operates as a biologics company. ReciBioPharm is a division of Recipharm.

Founded in 2014, Micron Biomedical is a clinical-stage biopharmaceutical company based in Atlanta, Georgia. It specializes in developing microneedle patches for vaccines, aiming to enhance protective effects and patient compliance while simplifying administration.

INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health.

AN2 Therapeutics is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines targeting infectious diseases. Established in 2017, the company focuses on advancing a clinical-stage antibacterial compound and has a strategic partnership with Brii Biosciences.

CanSino Biologics focuses on the R&D, manufacturing, and commercialization of vaccine products for human use. These vaccine products include pneumococcal polysaccharide and conjugate vaccines, and a DTcP-based combo, and other items. It is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.

Chemify specializes in developing a chemical digitization platform designed to facilitate drug and materials discovery as well as chemical synthesis. The company's innovative approach involves using automated synthetic hardware combined with digital XDL code to convert code into molecules on demand. This system is modular, universal, scalable, and teachable, making it highly versatile for various applications in chemical and material research. Chemify's software includes a unique chemical programming language and natural language recognition capabilities that translate synthetic procedures efficiently. Additionally, the platform features a comprehensive ontology that provides detailed insights into reaction conditions and flags potential issues, offering scientists real-time telemetry of reactions.

Radiant Biotherapeutics is a pioneering company developing a modular platform for creating multi-valent and multi-specific antibodies. This innovative approach aims to deliver transformative therapies for challenging diseases like cancer, autoimmune disorders, and infections by harnessing the power of avidity and multi-specificity.

Field develops pharmaceutical supply-chain technology that digitizes, modernizes, strengthens, and sustains healthcare supply chains, enabling easy access to medicines. The platform is designed to be easy to use, scalable, and effective for governments and businesses delivering healthcare worldwide, supporting improvements in how medicines reach communities and helping ensure healthcare for millions.

Eyam Vaccines and Immunotherapeutics is a life science and medical research company focused on the development of vaccines to combat infectious diseases. The company specializes in researching vaccines that target the spike glycoprotein, which is crucial for generating neutralizing antibodies against pathogens such as the novel coronavirus. Eyam employs a self-amplifying vaccine platform that enables the design of low-dose vaccines with advanced targeting capabilities, ensuring comprehensive protection, including against emerging variants. Through its innovative approach, the company aims to address pressing healthcare challenges and enhance public health outcomes.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

Ethris GmbH is a biotechnology company based in Planegg, Germany, specializing in the development of innovative therapeutic solutions for diseases with unmet medical needs. The company has a focus on transcript therapeutics, particularly through its SNIM RNA platform, which offers a novel approach to treating various conditions by enabling the production of therapeutic proteins within the patient’s body. This platform presents an alternative to traditional recombinant protein and gene therapies, addressing a range of diseases, including rare and genetically predetermined conditions. Ethris also develops Magnetovax, a personalized tumor vaccine platform that utilizes magnetic fields for localized activation in tumors. The company has established strategic research collaborations with major pharmaceutical firms, enhancing its capabilities in regenerative medicine and therapeutic development. Founded in 2009, Ethris continues to advance its technologies to meet diverse medical needs.

Surf Bio is a preclinical biopharmaceutical company focused on developing innovative therapeutic solutions through its next-generation surfactant technology. This novel biotechnology platform aims to enhance drug effectiveness across various therapeutic areas, including diabetes, oncology, infectious diseases, and gene therapy. By utilizing this advanced technology, Surf Bio seeks to provide healthcare organizations worldwide with access to improved drugs that can better address the needs of patients suffering from critical diseases.

Sibel Health develops wearable, clinical-grade digital health monitoring solutions for hospital and research use. The company focuses on wireless vital signs monitoring through soft, flexible sensors that are portable and user-friendly, enabling accurate data capture in clinical settings and during clinical trials. Its technology includes chest monitoring and limb sensors that measure heart rate, respiratory rate, skin temperature, body position and activity, supported by a physiological monitoring platform with analytics for both clinical care and research applications. The wearables are designed for neonatal care in the NICU as well as broader healthcare and pharmaceutical research contexts, offering biocompatible, silicone-based devices. The company aims to improve patient outcomes by providing continuous, real-time monitoring and data integration to support care decisions and study outcomes.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Antibody Solutions provides antigen design, polyclonal antibody generation, research and drug development for biopharmaceutical companies.

PhaSER Biomedical is Exploiting the 8HUM mouse, a unique mouse model with multiple utilities in drug discovery, and development.

Radiant Biotherapeutics is a pioneering company developing a modular platform for creating multi-valent and multi-specific antibodies. This innovative approach aims to deliver transformative therapies for challenging diseases like cancer, autoimmune disorders, and infections by harnessing the power of avidity and multi-specificity.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Founded in 2008, Ginkgo Bioworks designs, engineers, and licenses organisms for various applications. It discovers molecules for flavors, sweeteners, cosmetics, crops, pharmaceuticals, and generates probiotic bacteria for health benefits. The company serves markets such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

Naobios is a contract development and manufacturing organization (CDMO) located in Saint Herblain, France. The company specializes in bioprocess development and offers good manufacturing practice (GMP) production services for clinical batches of various biological products, including viral vaccines, oncolytic viruses, viral vectors, and challenge agents. With expertise in optimizing production processes, Naobios supports the development of live vaccine products, contributing to advancements in biopharmaceutical manufacturing.

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Founded in 2014, Micron Biomedical is a clinical-stage biopharmaceutical company based in Atlanta, Georgia. It specializes in developing microneedle patches for vaccines, aiming to enhance protective effects and patient compliance while simplifying administration.

Philips is a global technology company focused on health technology and improving people’s health and well-being through meaningful innovation. It offers a broad portfolio spanning diagnostic imaging, ultrasound, image-guided therapy, patient monitoring, health informatics, and consumer health products, as well as home care devices. The company operates across three segments—diagnosis and treatment, connected care, and personal health—and also develops lighting and consumer electronics for everyday use. Philips serves hospitals, clinics, and homes, applying advanced technologies to support prevention, diagnosis, treatment, and home-based care while pursuing sustainable, user-centered solutions.

Axmed is a business focuses on LMICs and strengthens the purchasing power of these markets to ensure the supply of cost-effective, high-quality medicines. We partner exclusively with authorized, high-quality pharmaceutical companies and certified caregivers to accelerate access to medicines.

CanSino Biologics Inc. is a biotechnology company based in Tianjin, China, focused on the research, development, manufacturing, and commercialization of vaccines. The company is actively developing a range of vaccines, including those for Ebola, meningitis, pertussis, and pneumococcal diseases, with multiple candidates currently in various phases of clinical trials. Notable products under development include the recombinant coronavirus vaccine Ad5-nCov, as well as several preclinical stage vaccines targeting adenovirus, Zika virus, meningitis, shingles, and polio. CanSino collaborates with the National Research Council of Canada to advance COVID-19 vaccine initiatives and has a co-development agreement with Precision NanoSystems to create an mRNA lipid nanoparticle vaccine against COVID-19. Founded in 2009, CanSino aims to meet the unmet medical needs in China and other emerging markets by providing high-quality vaccines at affordable prices.

AN2 Therapeutics is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative medicines targeting infectious diseases. Established in 2017, the company focuses on advancing a clinical-stage antibacterial compound and has a strategic partnership with Brii Biosciences.

GE Healthcare specializes in medical technology, offering a wide range of products including medical imaging systems, information technologies, diagnostics, patient monitoring devices, and biopharmaceutical manufacturing solutions. With a global presence, they aim to enhance patient care and outcomes through innovative healthcare solutions.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Aegis Life is a biotechnology company specializing in nucleic acid delivery technology, Fusogenix PLV. With over two decades of research, they focus on accelerating the discovery, clinical development, and manufacture of vaccines and therapeutics for infectious diseases.

The Medicines for All Institute, operating under the auspices of the Virginia Commonwealth University School of Engineering.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Smart Immune is a clinical‑stage biotechnology company developing next‑generation hematopoietic stem cell–based biotherapies to improve outcomes for patients with severe diseases. Its flagship program uses T‑cell progenitors (ProTcells) to enable rapid, polyclonal, and safe immune reconstitution after transplantation. The platform integrates targeted conditioning, gene therapy, and genome editing to extend treatment options for inherited blood disorders, blood cancers, and other life‑threatening conditions.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

DelSiTech Ltd., established in 2001 and headquartered in Turku, Finland, specializes in developing and licensing biodegradable silica-based drug delivery systems for controlled release of small molecule drugs, biopharmaceuticals, and viral vectors. The company focuses on parenteral and local administration, offering injectable depot, implant, and eye drop dosage forms. Its technology enables clients to address drug-related challenges in controlled release product development.

Zoetis Inc. is a prominent animal health company that specializes in the discovery, development, manufacture, and commercialization of medicines, vaccines, and diagnostic products for animals. The company serves both livestock, including cattle, swine, poultry, fish, and sheep, and companion animals such as dogs, cats, and horses. Its product portfolio includes vaccines designed to prevent various diseases, anti-infectives that target bacteria and parasites, and a range of other pharmaceuticals for pain management, dermatology, and reproductive health. Zoetis also offers diagnostic tools, including portable blood and urine analysis systems, and a variety of non-pharmaceutical products, such as nutritionals and agribusiness services. With a significant portion of its revenue coming from companion animal products, Zoetis has established itself as a leader in the animal healthcare industry, leveraging its market position to provide comprehensive solutions for veterinarians, livestock producers, and retail outlets. Founded in 1952 and headquartered in Parsippany, New Jersey, Zoetis was previously part of Pfizer's animal health unit.

UW Medicine is a clinical research and healthcare system that provides a higher degree of healthcare for pre-med students. UW Medicine health professionals provide the most up-to-date care for each individual patient through these integrated programs, lead one of the world's largest and most comprehensive medical research programs, and provide innovative learning programs for students, trainees, and practitioners in the health professions. UW Medicine, as the region's only comprehensive clinical, research, and learning health system, provides a higher level of healthcare, ranging from primary and preventive care to the most highly specialized care for the most complex medical conditions.

Aspen Pharmacare is a global pharmaceutical company that manufactures and supplies branded, generic, and specialty medicines across over 150 countries. Its portfolio includes general anaesthetics, muscle relaxants, anticoagulants, and other therapeutic areas. Aspen also offers contract manufacturing services for active pharmaceutical ingredients and finished dose forms.

ExploRNA Therapeutics specializes in developing innovative mRNA therapeutics for cancer treatments and vaccinations. Its proprietary technology enhances mRNA stability and translation efficiency, enabling the creation of adaptive immune responses.

Cyclica Inc. is a Toronto-based company that specializes in enhancing the drug discovery process through its integrated cloud-based platform augmented by artificial intelligence. Founded in 2010, Cyclica offers technologies such as Ligand Design, which generates novel molecules and evaluates their properties, and Ligand Express, a platform that screens small-molecule drugs against structurally-characterized proteins to assess poly-pharmacological profiles. The company's innovative software leverages biophysics and AI to identify potential ligand-protein interactions, enabling health institutions to prioritize candidate drugs, clarify adverse effects, and explore drug repurposing opportunities. Cyclica has also established a strategic partnership with AUM Biosciences to further its mission of improving drug discovery practices.

Bayer is a global life science company specializing in healthcare and agriculture. It focuses on developing and commercializing products and solutions based on scientific knowledge, with core competencies in pharmaceuticals, consumer health, and crop science.

Adapsyn Bioscience, founded in 2016 and based in Hamilton, Canada, is a biotechnology company focused on discovering and developing novel medicines derived from organic biomolecules. The company's primary product is the Adapsyn platform, which utilizes proprietary algorithms and artificial intelligence to analyze genomic and metabolomic data from microbes. This platform includes several key components: PRISM for identifying natural product biosynthetic gene clusters in microbial genomes; GARLIC for defining gene clusters that encode natural product drug variants and novel candidates; GRAPE for revealing evolved drug fragments from known products; and CLAMS for matching gene clusters to mass spectrometry peaks/compounds from complex mixtures. Adapsyn Bioscience leverages these advanced bioinformatic tools and state-of-the-art laboratory facilities to support researchers in identifying a diverse range of drugs, ultimately accelerating the discovery of medicines to combat various diseases.

Nuvisan is a global provider of pharmaceutical research services, based in Neu-Ulm, Germany. The company operates as a fully integrated contract research organization (CRO) and offers a wide range of product development and support services to the pharmaceutical, biotechnology, and medical device industries. Nuvisan's expertise encompasses early and clinical development, drug trials, bioanalytical analysis, pharmaceutical analysis, quality control, stability testing, and the management of test specimens. By delivering both individual tests and comprehensive drug development programs, Nuvisan supports clients throughout the various stages of drug development, facilitating the advancement of new therapies and medical innovations.

Manus Bio recreates plant processes in microorganisms using fermentation technology. This enables the production of natural ingredients such as flavors, fragrances, food ingredients, bio-pesticides, and pharmaceuticals, offering businesses affordable and sustainable solutions.

Bactolife is a company focused on addressing the global challenge of antimicrobial resistance through innovative solutions. It develops proprietary Binding Protein ingredients aimed at fortifying the gut microbiome, thereby reducing the risk of gastrointestinal infections in both humans and animals. Bactolife's platform is designed to neutralize harmful pathogens and their toxins while preserving beneficial microbes, thus promoting overall gut health. By enhancing gut microbiome modulation technologies, the company seeks to diminish reliance on traditional antimicrobials, ultimately improving health outcomes and contributing to the fight against antimicrobial resistance.

Celanese is a global technology and specialty materials company that engineers and manufactures a diverse range of products essential for everyday living. It is one of the world’s largest producers of acetic acid and its derivatives, which play a crucial role in various industries, including coatings and adhesives. Additionally, Celanese produces specialty polymers utilized in automotive, electronics, medical, building, and consumer markets. The company also manufactures cellulose derivatives, notably used in cigarette filters. With a strong commitment to research and development, Celanese focuses on innovation and provides opportunities for growth and advancement within a performance-driven culture. Its products are integral to the food, beverage, and pharmaceutical industries, reflecting the company's broad impact on daily life.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Iconovo is a Swedish device company that designs and licenses inhalation devices for pharmaceutical use. It develops multiple dry powder inhaler platforms, including a reservoir-based system, a capsule-based system, a unit-dose platform, and a pre-metered option, and it provides customized inhalation solutions to support both generic and innovative drug development. Founded in 2013 and headquartered in Lund, Iconovo collaborates with international pharmaceutical companies to advance inhaled medicines for respiratory conditions and other therapies. Its technology emphasizes safety, user-friendly design, and cost efficiency, with the aim of enabling development and commercialization of novel pharmaceuticals and vaccines and extending opportunities around patent expirations for established products. By offering protected inhaler technologies and development services, Iconovo seeks to serve customers across global markets.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

SwipeRx is a digital platform designed for pharmacies that connects pharmaceutical manufacturers, pharmacies, and patients. It offers specialized healthcare logistics, negotiated pricing, and financing solutions, creating the largest digital pharmacy purchasing network. The platform generates insights that enhance collaboration among pharmacies, improve pharmacist education, and strengthen market access. Additionally, it optimizes commercial strategies and boosts operational efficiencies, providing real-time access to patient and sales data. By doing so, SwipeRx enables its clients to improve patient affordability, access, and adherence to medications.

Aridis Pharmaceuticals is a late-stage biopharmaceutical company based in San Jose, California, founded in 2003. The company specializes in discovering and developing targeted immunotherapy treatments using fully human monoclonal antibodies (mAbs) to combat life-threatening infections. Its lead product candidate, AR-301, is currently in Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis Pharmaceuticals is advancing several other mAb candidates through various stages of clinical development, including AR-105 and AR-101 for gram-negative bacterial infections, AR-401 for Acinetobacter baumannii infections, AR-201 for respiratory syncytial virus, and AR-501 for chronic lung infections in cystic fibrosis patients. The company employs proprietary technology platforms to rapidly identify and manufacture these mAbs from patients who have successfully overcome infections, leveraging the natural potency of the human immune system.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Elarex, a Canadian healthcare technology company, specializes in developing and commercializing proprietary formulation technologies. Its flagship innovation, PT120, stabilizes biologicals, including live vaccines, enabling them to maintain full efficacy even when stored at 40°C, comparable to -80°C storage. This breakthrough allows for broader access to vaccines and biological drugs by facilitating transportation and storage in diverse environments, thereby enhancing global healthcare accessibility.

Providence Therapeutics is a Toronto-based biotechnology company focused on messenger RNA vaccine therapies, including personalized cancer vaccines that target tumor mutations and vaccines for infectious diseases such as COVID-19, delivered via lipid nanoparticles. It concentrates on oncology research, drug product development, and vaccine manufacturing, leveraging its expertise in mRNA to develop targeted treatments. Founded in 2015, Providence Therapeutics aims to advance medicines for diseases with unmet medical needs.

Mydawa operates an online pharmacy platform that connects patients directly with drug stores. It offers a wide range of high-quality medicines and wellness products, enabling consumers to purchase these affordably and conveniently via their mobile phones.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

Philips is a global technology company focused on health technology and improving people’s health and well-being through meaningful innovation. It offers a broad portfolio spanning diagnostic imaging, ultrasound, image-guided therapy, patient monitoring, health informatics, and consumer health products, as well as home care devices. The company operates across three segments—diagnosis and treatment, connected care, and personal health—and also develops lighting and consumer electronics for everyday use. Philips serves hospitals, clinics, and homes, applying advanced technologies to support prevention, diagnosis, treatment, and home-based care while pursuing sustainable, user-centered solutions.

Inventprise is a biotechnology company focused on the development of GMP vaccines, particularly a 25-valent pneumococcal conjugate vaccine (PCV). Founded in 2012 and based in Redmond, Washington, the company aims to provide large-scale vaccine supplies to low- and middle-income countries, significantly supported by funding from the Bill and Melinda Gates Foundation. In addition to its vaccine development efforts, Inventprise offers comprehensive outsourcing solutions for biopharmaceutical manufacturing, which include quality control assays, batch records, and necessary documentation. The company also provides in-person training and operates a fully equipped quality control laboratory for testing vaccine identity, potency, purity, and stability, thereby addressing health inequalities and promoting healthier lives globally.

Reithera Srl is a company devoted to develop and produce biopharmaceutical products based on gene delivery technologies for advanced therapies, in order to prevent and treat several serious or life-threatening diseases.

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on developing proprietary therapeutics for chronic diseases. The company utilizes its innovative ProNeura technology, a long-term drug delivery platform, to create products that maintain stable blood levels of medication over extended periods. Titan's principal product, Probuphine, is the first slow-release implant formulation of buprenorphine, designed for the outpatient treatment of opioid dependence. This implant allows for consistent medication delivery for up to six months, enhancing patient compliance and reducing the risk of misuse associated with traditional sublingual formulations. Additionally, Titan is developing ProNeura-Ropinirole, an implant for treating Parkinson’s disease, and a triiodothyronine implant for hypothyroidism. Established in 1992, Titan is committed to addressing serious medical disorders through its advanced drug delivery solutions.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Evotec is a drug discovery partnership firm that collaborates with pharmaceutical and biotechnology companies, academic institutions, and nonprofit organizations to advance innovative therapeutic solutions. The company specializes in a range of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. Approximately 80% of its revenue comes from shared research and development services, which involve fee-for-service work and integrated drug discovery collaborations utilizing proprietary assets. The remaining 20% of sales derive from its Just-Evotec Biologics segment, which provides contract development and manufacturing organization services for biologics. Evotec's approach emphasizes collaboration with various stakeholders, including patient advocacy groups and venture capitalists, to enhance drug discovery and development processes.

Atomwise, Inc. is a biotechnology company specializing in deep learning artificial intelligence technology for small molecule drug discovery. Based in San Francisco and founded in 2012, the company has developed AtomNet, a pioneering AI platform that facilitates virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical analysis of experimental affinity measurements and protein structures. Atomwise is focused on addressing over 600 unique disease targets and has established collaborations with over 250 partners, including prominent pharmaceutical and biotechnology firms. By leveraging its advanced technology, Atomwise aims to revolutionize the drug discovery process and advance a pipeline of small-molecule drug candidates into preclinical studies. The company was previously known as Chematria, Inc. and rebranded to Atomwise, Inc. in 2015.

Sapient enables the discovery of circulating small molecule biomarkers at unprecedented speed and scale. Leveraging next-generation mass spectrometry, biocomputational analysis, and large-scale human biology databases, its platform supports the rapid identification and validation of circulating biomarkers of health, disease, and drug response which are needed to align patients, disease biology, and specific therapies.

Dynavax Technologies Corporation is a biopharmaceutical company specializing in the development and commercialization of innovative vaccines. Its flagship product, HEPLISAV-B, is a recombinant adjuvanted hepatitis B vaccine approved for use in adults aged 18 years and older, targeting all known subtypes of the hepatitis B virus. The company utilizes its proprietary Toll-like Receptor Immune Modulation Platform to enhance both innate and adaptive immune responses. Dynavax is actively advancing its immuno-oncology portfolio and has several development-stage products, including SD-101 and DV281, aimed at various cancer indications. In addition, the company engages in multiple research collaborations to develop adjuvanted vaccines for infectious diseases, including COVID-19, partnering with organizations such as Clover Biopharmaceuticals, the University of Queensland, and the Coalition for Epidemic Preparedness Innovations. Established in 1996 and headquartered in Emeryville, California, Dynavax continues to expand its role in vaccine development.

HJF Medical Research International is an NGO that supports international programs advancing medical research and HIV prevention.

A-Alpha Bio, Inc. is a biotechnology company specializing in synthetic biology and advanced quantitative measurement of protein interactions to facilitate drug development. Founded in 2017 and headquartered in Seattle, Washington, the company offers its proprietary AlphaSeq platform, which enables high-throughput mapping of protein-protein interactions. This technology allows for the simultaneous identification and quantification of interactions among thousands of protein pairs, streamlining the drug discovery process by aiding in the identification of potential drug targets and enhancing the understanding of disease mechanisms. By providing biologics and molecular glue discovery and optimization services, A-Alpha Bio supports pharmaceutical companies in optimizing binding and specificity to multiple target proteins. The team comprises synthetic biologists, structural biologists, and next-generation sequencing experts dedicated to overcoming challenges in the drug development process.

Immunocore is a biotechnology company focused on developing novel T cell receptor-based therapies to treat diseases with high unmet needs, such as cancer and viral infections. Its proprietary platform enables the creation of bispecific immunotherapies, with IMCgp100 being its lead clinical candidate for metastatic melanoma.

Almac Group is a global contract development and manufacturing organization that provides a comprehensive suite of services to pharmaceutical and biotechnology companies. Its offerings span research and development, biomarker discovery, active pharmaceutical ingredient production, formulation development, clinical trial supply, interactive voice response system technology, commercial‑scale manufacturing, and companion diagnostic development. Founded more than four decades ago, the privately held company employs over 4,500 professionals and is headquartered in Craigavon, Northern Ireland. Almac operates facilities across the United Kingdom, Ireland, the United States (Pennsylvania, North Carolina, California), and Asia (Singapore, Tokyo), and continually invests in advanced capabilities such as biocatalytic API synthesis, clinical trial data management, and the clinical supply chain. The organization also encompasses specialized units, including Almac Sciences, which offers analytical testing for drug substances and products, and Almac Discovery, a research‑driven oncology company focused on early‑stage drug discovery.

MedinCell S.A. is a pharmaceutical company focused on developing innovative therapeutic solutions through its proprietary BEPO technology, which facilitates long-acting injectable products utilizing biodegradable polymers and a biocompatible solvent. Based in Jacou, France, the company is engaged in ongoing research and development to optimize the efficiency and accessibility of medical treatments across various therapeutic areas. MedinCell's product pipeline includes several candidates, such as mdc-IRM, a subcutaneous injection for schizophrenia currently in Phase III trials, and mdc-CWM, an intra-articular injection aimed at treating pain and inflammation. Additionally, the company is exploring formulations like mdc-WWM for contraception and mdc-ANG for central nervous system disorders, alongside other candidates targeting pain management and organ transplant applications. Through its advancements in controlled, long-acting injectables, MedinCell aims to enhance treatment outcomes for patients.

Enesi Pharma is an innovative pharmaceutical company developing novel products with potential to transform performance and delivery of vaccines and make a material impact on global healthcare. The company’s primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, working in partnership with global companies, government agencies and non-governmental organizations.

one.bio is a biotechnology company spun out from UC Davis that develops naturally derived oligosaccharides using proprietary technology to convert natural products into novel ingredients. The focus is on producing oligosaccharides that modulate the microbiome and immune function for applications in food, agriculture, and biopharmaceuticals. By supplying clients with novel prebiotics, symbiotics, and immunomodulatory ingredients, the company aims to support health outcomes in humans and animals. Leveraging its specialized platform, one.bio pursues ingredients that can influence gut microbiota, nutrient absorption, and immune responses, positioning itself at the intersection of nutrition and therapeutics.

Credence MedSystems is a medical technology company specializing in drug delivery systems. It develops and manufactures safety syringes designed to enhance patient and caregiver safety, simplify commercialization paths for pharmaceutical partners, and reduce risks in healthcare settings.

Lyndra Therapeutics develops ultra‑long‑acting oral medicines that release drugs over periods of up to a month while temporarily residing in the stomach. The company focuses on sustained, steady‑state delivery for conditions such as Alzheimer’s disease, cardiovascular and metabolic disorders, psychiatric and opioid use disorders, immunology, HIV, malaria vector control, and oral contraceptives. Founded in 2015 and headquartered in Watertown, Massachusetts, Lyndra’s platform aims to improve medication adherence and reduce healthcare costs by enabling once‑weekly or monthly dosing of approved drugs and novel therapeutics.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Medsaf operates an end-to-end pharmaceutical procurement and distribution platform in Nigeria that connects hospitals, pharmacies, and patients to affordable, quality medications with timely delivery. The platform combines an online marketplace with blockchain-backed track-and-trace, data analytics, and embedded financing to improve efficiency, safety, and transparency across the pharmaceutical supply chain. It provides quality-control as a service and links manufacturers, vetted suppliers, and logistics providers to health-care buyers, enabling automated procurement and financing options, including buy-now-pay-later for medication procurement. Based in Lagos, the company aims to streamline procurement, enhance visibility into the movement of medicines, and ensure reliable access to medications for health-care providers and consumers.

Iyeza Health specializes in supply chain management and distribution services for healthcare products, focusing on medications for individuals with chronic conditions such as diabetes and hypertension. The company operates primarily within South Africa.

Manus Bio recreates plant processes in microorganisms using fermentation technology. This enables the production of natural ingredients such as flavors, fragrances, food ingredients, bio-pesticides, and pharmaceuticals, offering businesses affordable and sustainable solutions.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

DelSiTech Ltd., established in 2001 and headquartered in Turku, Finland, specializes in developing and licensing biodegradable silica-based drug delivery systems for controlled release of small molecule drugs, biopharmaceuticals, and viral vectors. The company focuses on parenteral and local administration, offering injectable depot, implant, and eye drop dosage forms. Its technology enables clients to address drug-related challenges in controlled release product development.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that aims to radically improve patients’ lives by decoding biology through the integration of biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company operates a large-scale drug discovery platform built around Recursion OS, an infrastructure layer and a Map of proprietary biological and chemical data, supported by software tools and machine learning to explore biology beyond human bias and identify new therapeutic opportunities. Its platform includes ReChem for selecting and designing compounds, ReScreen and ReScreenRun for planning and automating large-scale experiments, and ReRun, ReAnalyze, and RePredict for digital signatures, data analysis, and predictive modeling of drug relationships. Founded in 2013, the company is based in Salt Lake City, Utah.

Scripps Research, established in 1924, is a prominent, not-for-profit biomedical research institution with campuses in La Jolla, CA, and Jupiter, FL. Employing around 3,000 people, it's renowned for its contributions to science and health, including breakthroughs in cancer, rheumatoid arthritis, and hemophilia treatments. The institute, which ranks among the top ten for its graduate program in biology and chemistry, is led by distinguished scientists, including Nobel laureates. Its drug discovery and development division, Calibr, collaborates with scientists to expedite the delivery of innovative medicines to patients. Scripps Research is recognized as a leader in biomedical innovation, ranking No.1 by the Nature Index.

Novartis is a global healthcare company based in Switzerland, providing innovative medicines and solutions to address evolving patient needs worldwide. With over 100,000 employees across 140 countries, they focus on discovering new treatments in areas such as oncology, immunology, neuroscience, and cardiovascular diseases.

Manus Bio recreates plant processes in microorganisms using fermentation technology. This enables the production of natural ingredients such as flavors, fragrances, food ingredients, bio-pesticides, and pharmaceuticals, offering businesses affordable and sustainable solutions.

Visterra is a clinical-stage biopharmaceutical company developing precision antibody-based medicines for hard-to-treat infectious and non-infectious diseases. It uses its Hierotope platform to engineer monoclonal antibodies targeting various pathogens, including influenza A, dengue virus, Pseudomonas aeruginosa, and Immunoglobulin A Nephropathy.

PnuVax Incorporated is dedicated to the production of high quality biopharmaceuticals for the promotion of public health worldwide. Their team has over 30 years of experience in the pharmaceutical industry, from research to full scale production.

Immunocore is a biotechnology company focused on developing novel T cell receptor-based therapies to treat diseases with high unmet needs, such as cancer and viral infections. Its proprietary platform enables the creation of bispecific immunotherapies, with IMCgp100 being its lead clinical candidate for metastatic melanoma.

Elanco is a global animal health company focused on enriching the lives of both people and animals. Their mission is centered around the belief that food and companionship are essential elements of a fulfilling life. With a commitment to advancing animal health and well-being, Elanco serves as a trusted partner for veterinarians, farmers, and pet owners worldwide. Through their innovative products and solutions, Elanco strives to improve the health and quality of life for animals, ultimately benefiting society as a whole.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Arsanis, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in monoclonal antibody (mAb) immunotherapies for serious infectious diseases. Founded in 2010, Arsanis focuses on developing innovative therapies targeting various bacterial and viral pathogens. Its lead clinical program, ASN100, is currently in a Phase 2 trial aimed at preventing Staphylococcus aureus pneumonia in high-risk, mechanically ventilated patients. The company's preclinical pipeline includes mAbs directed against respiratory syncytial virus and Gram-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli. Arsanis leverages advanced mAb discovery techniques to create a diverse range of therapeutic candidates with multiple mechanisms of action, addressing the urgent need for effective treatments in infectious disease management. The company also has research and preclinical development operations in Vienna, Austria, under Arsanis Biosciences GmbH.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the discovery and development of fully human monoclonal antibody therapeutics. Founded in 2009, Kymab utilizes its proprietary Kymouse and IntelliSelect platforms to develop therapies targeting challenging and novel drug targets within immuno-oncology and immune-mediated diseases. The company's comprehensive antibody platforms are designed to maximize the diversity of human antibodies, enabling the creation of novel therapeutic options for conditions such as cancer and autoimmune diseases. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to advance its research and development efforts. As a subsidiary of Kymab Group Limited, the company is focused on addressing unmet medical needs through innovative antibody-based therapies.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, specializing in the discovery and development of fully human monoclonal antibody therapeutics. Founded in 2009, Kymab utilizes its proprietary Kymouse and IntelliSelect platforms to develop therapies targeting challenging and novel drug targets within immuno-oncology and immune-mediated diseases. The company's comprehensive antibody platforms are designed to maximize the diversity of human antibodies, enabling the creation of novel therapeutic options for conditions such as cancer and autoimmune diseases. Kymab has established strategic collaborations with Heptares Therapeutics and LifeArc to advance its research and development efforts. As a subsidiary of Kymab Group Limited, the company is focused on addressing unmet medical needs through innovative antibody-based therapies.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company based in Hangzhou, China, that specializes in the development of antibody and recombinant protein biotherapeutics. Founded in 2016, the company focuses on leveraging its expertise in molecular design, process design, and drug product design to facilitate the development of biologics. By employing advanced protein, process, and manufacturing sciences, Hangzhou Just Biotherapeutics aims to overcome technical challenges associated with protein therapeutics, thereby accelerating development timelines and significantly lowering manufacturing costs. As a subsidiary of MabSpace Biosciences Co., Ltd., the company positions itself as a key player in the biopharmaceutical sector, dedicated to enhancing the efficiency of biomedical innovation.

Takeda Ventures is a strategic investment arm of Takeda Pharmaceutical Company Limited, focusing on direct and fund-of-fund investments in healthcare and life sciences sectors. It specializes in seed to mid-stage investments, with a primary focus on therapeutics, regenerative medicines, RNA/DNA modulation, and innovative protein/peptide biologics. The firm invests globally but has a strong presence in the United States, Canada, and Europe.